Immunophotonics is a clinical-stage biotech pioneering Interventional Immuno-Oncology with lead candidate IP-001, a proprietary glycan polymer that functions as both an antigen depot and a potent immune activator. IP-001 is designed to prolong the availability of tumor antigens liberated by ablation, recruit and activate antigen-presenting cells, increase antigen uptake, and elicit downstream adaptive immune responses. The company is using proceeds from a $21.4 million equity financing to transition IP-001 into Phase 2a development across a variety of solid tumor indications and to fund non-clinical research in oncology and infectious disease. Immunophotonics recently completed a Phase 1b trial in thermally ablated solid tumors, received a $2.4 million non-dilutive SBIR grant from the National Cancer Institute, and has patents covering IP-001 in over 40 additional countries. The company is based in St. Louis, Missouri, with subsidiaries in Bern, Switzerland and Tianjin, China, and plans to expand clinical trials into additional countries and cancer indications. Academic collaborators have published related findings in multiple peer-reviewed journals, and the company has appointed additional board members to support development.

Total raised

$21M

Funding rounds

1

Latest round

Series B

Latest activity

Apr 2022